RxSight Awards New-Hire Equity to Two Employees
RxSight granted stock options for 236,456 shares to two new non-executive employees on October 23, 2026, with an exercise price of $5.02 per share. The company also agreed to issue restricted stock units covering 637,449 shares on or about November 3, 2026, under its 2026 Inducement Equity Incentive Plan and Nasdaq Listing Rule 5635(c)(4). The awards vest over time and require continued service, with options vesting 25% after one year and then monthly, while the RSUs vest in six installments from February 2027 through August 2029.
RxSight disclosed that its October 23, 2026, inducement award to two newly hired non-executive staff consists of options on 236,456 shares priced at $5.02, matching that day’s closing price. The options become exercisable as to one quarter after a year, then in monthly increments over the following three years, provided the recipients remain employed.
Separately, the company expects to issue RSUs for 637,449 shares around November 3, 2026, under its 2026 Inducement Equity Incentive Plan, relying on Nasdaq Rule 5635(c)(4). Those units are scheduled to vest in six equal portions between February 2027 and August 2029, also contingent on continued service.
The grants may affect current shareholders through possible dilution, while giving the two new employees a stake tied to continued service. Because the awards are small relative to broad labor markets, their societal effect is likely limited; however, they illustrate how public companies use equity to recruit non-executive talent. Observers may watch whether such inducements align worker incentives with long-term performance or simply transfer value, but the outcome is uncertain.